Schering-Plough's boceprevir continues to show promise in hepatitis C
This article was originally published in Scrip
Executive Summary
Schering-Plough's investigational hepatitis C therapy boceprevir has continued to show promise in a Phase II trial, with a doubling of the sustained virologic response (SVR) compared with control therapy.